## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

§

§ §

§

PABilication of: Sessler, et al.

Serial No.: 09/939,514

Filed: August 24, 2001

For: HALOGENATED CALIXPYRROLES, CALIXPYRIDINOPYRROLES, AND CALIXPYRIDINES, AND USES THEREOF

U.S. Patent and Trademark Office P. O. Box 2327 Arlington, VA 22202

Customer No.: 020790

## **INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 CFR §§1.56, 1.97 and 1.98, record is being made below of documents which the Patent Office is requested to consider in connection with examination of the above-identified patent application.

As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 CFR §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind and specifically is not an admission that the documents listed on attached Form PTO-1449 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 CFR §1.56(b).

The present application is a continuation-in-part application of copending USSN 09/838,998, filed April 20, 2001, which is a divisional application of then copending USSN 08/833,379, filed April 4, 1997, now U.S. 6,262,257, to which the present application claims priority for an earlier effective filing date under §120. Accordingly, copies of references provided in priority case USSN 08/833,379 and USSN 09/838,998 are not provided; however, copies of references A3 – A4, and C87 – C104 are provided herewith.

The inventors of claims 1-21, 29 and 30 are Jonathan L. Sessler, Pavel Anzenbacher, Jr., James Shriver, and Manuel Marquez. The inventor of claims 22-28 and 30 is Jonathan L. Sessler. It is respectfully requested that the documents be carefully considered by the Examiner and made of record in the case. It is also requested that the Examiner initial the PTO-1449 Form (7 pages) and return a copy of the initialed form to Applicant's agent, Dr. Gloria L. Norberg.

The present Information Disclosure Statement is believed to be timely filed in accordance with 37 C.F.R §1.97(b)(1). No fees are believed to be due in connection with the filing of this Information Disclosure Statement; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fee from Akin, Gump, Strauss, Hauer & Feld, L.L.P. Deposit Account No.01-0660.

Respectfully submitted,


By Clari


Gloria L. Norberg

Agent for Applicant(s) Registration No. 36,706

Date: November 20, 2001

Akin, Gump, Strauss, Hauer & Feld, L.L.P. 816 Congress Avenue, Suite 1900 Austin, Texas 78701 (512) 499-6200





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Sessler, et al.

Serial No.: 09/939,514

Filed: August 24, 2001

For: HALOGENATED CALIXPYRROLES, CALIXPYRIDINOPYRROLES, AND CALIXPYRIDINES, AND USES THEREOF Examiner: Joseph K. McKane and R

(in parent application)

Group Art Unit: 1626

Atty. Dkt. No.: 045404.0003

Express Mail Label: EL576204784US

Customer No.: 020790

U.S. Patent and Trademark Office P. O. Box 2327 Arlington, VA 22202

## TRANSMITTAL LETTER

Dear Sir:

With regard to the above-identified application, enclosed please find:

- 1. Information Disclosure Statement;
- 2. Form PTO-1449 (7 pages);
- 3. Copy of references A3 A4, and C87 C104; and
- 4. Return postcard. Please date stamp and mail the return postcard.

No fees are believed to be due with the filing of this Information Disclosure Statement. However, if fees are deemed necessary, the Commissioner is authorized to charge said fees to Akin, Gump, Strauss, Hauer & Feld, L.L.P., Deposit Account No. 01-0660.

Respectfully Submitted,

November 20, 2001

By: Gloria L. Norberg

Reg. No.: 36,706

Agent for Applicants